Brain Cancer Clinical Trial
— RESISTOfficial title:
The Impact of Resistance ExerciSe on Muscle Mass in GlioblaSToma Survivors (RESIST)
Verified date | March 2024 |
Source | Nova Scotia Health Authority |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Glioblastoma patients are confronted with a debilitating disease associated with a low survival rate and poor quality of life. The goal of this study will be to reach a largely underrepresented population in the exercise literature and explore the role of a tailored circuit-based resistance training program on functional fitness (i.e., ability to carry out tasks of daily living) and associated health outcomes (e.g., quality of life) for GBM patients on active treatment.
Status | Enrolling by invitation |
Enrollment | 24 |
Est. completion date | December 31, 2025 |
Est. primary completion date | December 31, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - histologically confirmed diagnosis of either primary or secondary GBM - received any dose of DEX - Karnofsky Performance Status (KPS) >70 - English fluency - physician approval - willingness to travel to Halifax to participate. Exclusion Criteria: - unstable or symptomatic cardiac or pulmonary disease, injury or co-morbid disease that precludes ability to safely exercise - significant cognitive limitations - uncontrolled seizures associated with impaired awareness |
Country | Name | City | State |
---|---|---|---|
Canada | QEII Health Sciences Centre | Halifax | Nova Scotia |
Lead Sponsor | Collaborator |
---|---|
Nova Scotia Health Authority | Canadian Cancer Society (CCS) |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Study Feasibility - Participant Accrual | Participant accrual calculated as % of patients referred divided by number of patients consented to participation | Captured over the 12-week study period | |
Other | Study Feasibility - Participant Attrition | Participant attrition calculated as % of patients who complete 12-week study divided by number who withdraw from study | Captured over the 12-week study period | |
Other | Study Feasibility - Participant Adherence | Participant program adherence calculated as % of exercise sessions completed divided by total number of available exercise sessions over 12-week intervention | Captured over the 12-week study period | |
Other | Study safety | Adverse events will be recorded | Captured over the 12-week study period | |
Primary | Functional Performance | Short Physical Performance Battery to assess activities of daily living | Baseline to post-intervention (12-week) change | |
Primary | Grip strength | Measured by handheld dynamometer | Baseline to post-intervention (12-week) change | |
Secondary | Body Mass Index (BMI) | Weight (kg) and height (m) will be used to calculate BMI | Baseline to post-intervention (12-week) change | |
Secondary | Body composition and Muscle Mass | Arm, waist, and calf circumference (cm) | Baseline to post-intervention (12-week) change | |
Secondary | Muscle Mass | Muscle mass and quality - 3T diagnostic magnetic resonance imaging | Baseline to post-intervention (12-week) change | |
Secondary | Aerobic fitness | 6 minute walk will be used to calculate aerobic fitness | Baseline to post-intervention (12-week) change | |
Secondary | Physical activity | Godin Leisure Time Physical Activity Questionnaire - Leisure Score Index will be used to calculate self-reported leisure physical activity | Baseline to post-intervention (12-week) change | |
Secondary | Physical, functional, emotional, and social/family quality of Life | Functional Assessment of Cancer Therapy - Brain (FACT-Br) - 50 item scale; total scale score range 0-200; higher scores indicate higher overall QOL | Baseline to post-intervention (12-week) change | |
Secondary | Fatigue | Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) - 13 item scale; score range 0-52; higher scores indicate less fatigue | Baseline to post-intervention (12-week) change | |
Secondary | Cognitive functioning 1 | Trail making test-b; Time taken to complete each task and number of errors made during each task are recorded and compared with normative data. Time to complete the task is recorded in seconds; the greater the number of seconds to complete the task, the greater the impairment. | Baseline to post-intervention (12-week) change | |
Secondary | Cognitive functioning 2 | Hopkins Verbal Learning Test-Revised for memory; total recall and recognition scores will be calculated | Baseline to post-intervention (12-week) change | |
Secondary | General Health (EuroQol) 5 Dimension - 5 Level | Mobility, self-care, usual activities, pain/discomfort, anxiety/depression (EuroQol-5Dimension-5Level; EQ-5D-5L) - 5 dimensions; higher scores indicate higher problems | Baseline to post-intervention (12-week) change | |
Secondary | General Health (EuroQol) Visual Analog Scale | EuroQol Visual Analog Scale 0-100; lower scores indicate worse health | Baseline to post-intervention (12-week) change |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05023434 -
A Study to Measure the Effect of Brain Stimulation on Hand Strength and Function in Patients With Brain Tumors
|
||
Terminated |
NCT01902771 -
Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors
|
Phase 1 | |
Completed |
NCT04114786 -
3D Printed Mask for GBM and Brain Mets
|
N/A | |
Recruiting |
NCT04367779 -
Research of Biomarkers of Response to Proton Beam Therapy in Pediatric and Adult Patients.
|
||
Recruiting |
NCT06058988 -
Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer
|
Phase 2 | |
Completed |
NCT02852655 -
A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma
|
Phase 1 | |
Completed |
NCT02911155 -
Cancer and Other Disease Risks in U.S. Nuclear Medicine Technologists
|
||
Completed |
NCT00329589 -
A Trial Using Velcade Plus Chemoradiation for Central Nervous System, Head and Neck, and Cervical Cancer Patients
|
Phase 1 | |
Completed |
NCT01650922 -
Molecular Genetic Studies of Childhood Brain Tumors and Blood Samples
|
N/A | |
Completed |
NCT00505141 -
Urban Environmental Exposures and Childhood Cancer
|
N/A | |
Completed |
NCT00504660 -
6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients
|
Phase 2 | |
Completed |
NCT00979810 -
Image-Guided Stereotactic Biopsy of High Grade Gliomas
|
N/A | |
Recruiting |
NCT04899908 -
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
|
Phase 2 | |
Active, not recruiting |
NCT02851706 -
Natural History of and Specimen Banking for People With Tumors of the Central Nervous System
|
||
Completed |
NCT02798406 -
Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects
|
Phase 2 | |
Completed |
NCT01012609 -
External Beam Radiation Therapy and Cetuximab Followed by Irinotecan and Cetuximab for Children and Young Adults With Newly Diagnosed Diffuse Pontine Tumors and High-Grade Astrocytomas
|
Phase 2 | |
Completed |
NCT00782756 -
Bevacizumab, Temozolomide and Hypofractionated Radiotherapy for Patients With Newly Diagnosed Malignant Glioma
|
Phase 2 | |
Terminated |
NCT03149575 -
VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM
|
Phase 3 | |
Completed |
NCT01974804 -
Assessment of Early Treatment Response by Diffusion and Perfusion MRI in Patients With Brain Metastasis
|
||
Withdrawn |
NCT01320787 -
18-F-Fluoroacetate as PET Imaging Agent
|
Phase 1 |